SI-BONE (SIBN) Competitors

LivaNova (NASDAQ:LIVN) and SI-BONE (NASDAQ:SIBN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.

Do analysts prefer LIVN or SIBN?

LivaNova presently has a consensus target price of $59.29, suggesting a potential upside of 26.95%. SI-BONE has a consensus target price of $22.50, suggesting a potential upside of 19.62%. Given LivaNova's higher probable upside, equities analysts clearly believe LivaNova is more favorable than SI-BONE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
SI-BONE	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in LIVN or SIBN?

LivaNova received 234 more outperform votes than SI-BONE when rated by MarketBeat users. Likewise, 69.80% of users gave LivaNova an outperform vote while only 69.17% of users gave SI-BONE an outperform vote.

Company	Underperform	Outperform
LivaNova	Outperform Votes 409 69.80%	Underperform Votes 177 30.20%
SI-BONE	Outperform Votes 175 69.17%	Underperform Votes 78 30.83%

Which has more risk & volatility, LIVN or SIBN?

LivaNova has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Is LIVN or SIBN more profitable?

LivaNova has a net margin of 1.91% compared to SI-BONE's net margin of -23.82%. LivaNova's return on equity of 13.81% beat SI-BONE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	1.91%	13.81%	7.07%
SI-BONE	-23.82%	-22.51%	-16.53%

Which has stronger earnings and valuation, LIVN or SIBN?

LivaNova has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.28B	2.00	$17.55M	-$4.09	-11.42
SI-BONE	$176.60M	4.54	-$43.34M	-$0.64	-29.39

Does the media prefer LIVN or SIBN?

In the previous week, SI-BONE had 4 more articles in the media than LivaNova. MarketBeat recorded 9 mentions for SI-BONE and 5 mentions for LivaNova. SI-BONE's average media sentiment score of 1.21 beat LivaNova's score of 0.35 indicating that SI-BONE is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
SI-BONE	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in LIVN or SIBN?

97.6% of LivaNova shares are held by institutional investors. Comparatively, 98.1% of SI-BONE shares are held by institutional investors. 0.3% of LivaNova shares are held by company insiders. Comparatively, 4.0% of SI-BONE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

LivaNova beats SI-BONE on 11 of the 18 factors compared between the two stocks.